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Abstract. Nefazodone, a phenytpiperazine antidepressant, 
exhibits novel dual activity on serotonin (5-HT) neurons; 
it binds to 5-HT2 receptors and inhibits 5-HT reuptake. 
Flexible doses of nefazodone (100-400 mg/day) and amit- 
riptyline (50-200 mg/day) were compared in 106 major 
depressive inpatients in a 6-week double-blind study. Re- 
sults showed significant superiority of amitriptyline over 
nefazodone on all rating instruments: Montgomery and 
Asberg depression rating scale (P < 0,0001), Hamilton 
depression scale (P < 0.0006), Clinical Global Impres- 
sions (P<0.0001) and Patient Global Assessment 
(P < 0.01). A total of 65% of patients under amitriptyline 
and 56% of patients under nefazodone reported adverse 
events during the study, with significantly more dry 
mouth in the amitriptyline group (39% versus 11%, 
P = 0.001). Modal daily doses within the last treatment 
week reached 242 mg with nefazodone and 124 mg with 
amitriptyline. The lower efficacy of nefazodone, which 
contradicts comparative trials with imipramine in US 
patients, is discussed with regard to the dose of 
nefazodone, probably below the optimal therapeutic 
range for melancholic patients, and to the clinical differ- 
ences between the patient samples. 
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Nefazodone is a chemical and pharmacological analogue 
of trazodone and a member of the phenylpiperazine class 
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of antidepressants. The pharmacological profile of 
nefazodone resembles trazodone but is clearly distinct 
from other antidepressants. Nefazodone exhibits novel 
dual activity on serotonin (5-HT) neurons: it binds with 
selectivity and high affinity to central 5-HT2 receptors on 
the one hand and inhibits cortical 5-HT reuptake on the 
other hand (Eison et al. 1990). Chronic treatment with 
nefazodone downregulates cortical 5-HTz receptors and 
results in a dose-dependent reduction in 5-HTrmediated 
behavioral responses while enhancing 5-HT1A-mediated 
neurotransmission, thereby increasing serotonergic neur- 
otransmission (Andrade and Nicoll 1987; Eison et al. 
1990). Unlike trazodone, nefazodone is active in several 
classical antidepressant screening tests such as reversal of 
reserpine-induced ptosis (Eison et al. 1990). Moreover, 
nefazodone also exhibits all characteristics of antidepress- 
ant potential in mechanism-independent behavioral 
models such as learned helplessness and the differential 
reinforcement for low rates of response-72 s paradigm 
(DRL-72) (Eison et al. 1990). Nefazodone is devoid of 
anticholinergic activity, exhibits no cardiac toxicity, has 
no affinity for histamine receptors and has less affinity for 
cq-adrenergic receptors compared to most other antide- 
pressants, and in particular trazodone. 
Therefore, the preclinical profile of nefazodone sugges- 
ted that it may be a more effective antidepressant than 
trazodone with a lower incidence of sedation, hypoten- 
sion, and other adverse events mediated through c~-ad- 
renergic blockade. The antidepressant efficacy of 
nefazodone has already been demonstrated as superior to 
placebo or equivalent to imipramine in several US studies 
among major depressive outpatients (Feighner et al. 1989; 
D'Amico et at. 1990). The purpose of the present trial was 
to confirm the antidepressant potential of nefazodone in 
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major  depressive inpatients.  As will be discussed, we felt 
that  depressive inpat ients  represent a par t icular  subgroup  
more  suitable to demonst ra te  differences in the clinical 
activity of ant idepressants  (Ansseau 1992). 
Materials and methods 
Design of the study. The study was performed between December 
1989 and April 1991 in ten Belgian centers used to collaborating 
(Ansseau et al. 1989a, b, 1991b) and exhibiting excellent reliability in 
clinical ratings (see affiliations). The number of patients enrolled at 
each site ranged from 5 to 24 with a median of 11 inclusions. The 
trial used a double-blind design with two parallel groups of patients 
randomly assigned to flexible doses of nefazodone or amitriptyline. 
After an initial dose of nefazodone 100 mg or amitriptyline 50 mg at 
bedtime for the first 2 days, the dosage was titrated between 100 and 
300 mg for nefazodone and between 50 and 150 mg for amitriptyline 
during the first 3 weeks and between 100 and 400 mg for nefazodone 
and 50 and 200 mg for amitriptyline for the subsequent 3 weeks. The 
dosages were determined by the investigator on the basis of the 
clinical response and the adverse experience profile of each patient. 
Due to a general impression of the investigators of low overall 
therapeutic efficacy, an interim analysis was performed using the 
data of 69 patients who had completed the study. This analysis 
revealed 61% of treatment responders, as defined by a rating of 
much or very much hnproved on the clinical global impressions 
(CGI) (Guy 1976). Nonresponders were characterized by lower daily 
dosage than responders during the first 2 weeks of treatment: 3.5 
versus 3.67 tablets during week 1 and 3.89 versus 4.29 during week 2. 
Therefore, an amendment was adopted for the remaining patients 
(26% of the sample) which specified that the daily doses were 200 mg 
for nefazodone and 100 mg for amitriptyline during week t, between 
100 and 400 mg for nefazodone and 50 and 200 mg for amitriptyline 
during week 2, and between 200 and 400 mg for nefazodone and 100 
and 200 mg for amitriptyline during the following 4 weeks. 
The study drugs were presented as nefazodone 50 mg or amitri- 
ptyline 25 mg tablets and administered in two daily intakes, morning 
and evening, until a maximal daily dose of nefazodone 300 mg or 
amitriptyline 150 mg, and in three daily intakes, morning, noon, and 
evening for higher doses. Compliance was controlled by drug count; 
plasma monitoring was not performed. The active period was pre- 
ceded by a drug-free period of 4 days to 4 weeks. No other psycho- 
tropic mediation was taken, except for occasional lormetazepam at 
a low dose as hypnotic. Moreover, other therapeutic interventions 
(e.g., formal psychotherapy) were not allowed during the trial. The 
duration of the study was 6 weeks, with assessments at baseline and 
after 1, 2, 3, 4, and 6 weeks of treatment. The trial was monitored 
according to all principles of European and US good clinical prac- 
tice (Minist~re de Affaires Sociales et de l'Emploi 1987; Mathieu 
1990). 
Subjects. A total of 106 inpatients were included in tile study: 55 in 
the nefazodone group and 51 in the amitriptyline group. Patients 
were 32 men and 74 women, aged 24-79 years, with a mean age (SD) 
of 47.2 (13.4) years. All subjects were depressed inpatients who 
fulfilled DSM-III-R criteria for moderate or severe major depression 
(99 patients) or bipolar disorder, depressed (7 patients) (American 
Psychiatric Association 1987) and had a score of at least 27 on the 
Montgomery and Asberg depression rating scale (MADRS) (Mon- 
tgomery and Asberg 1979). Fifty-nine (56%) patients also met DSM- 
III-R criteria for melancholia. Patients presenting any evidence of 
contraindications for a tricyclic antidepressant, or serious or uncon- 
trolled medical illness, were excluded from the study. The demo- 
graphic and clinical characteristics of the patients are presented in 
Table 1. No statistically significant differences existed between the 
treatment groups. 
All patients remained hospitalized for at least the screening 
phase and the first 2 weeks of treatment. The protocol obtained the 
approval of the Ethical Committee of the University of Li6ge Medi- 
cal School and all patients were fully informed of the purpose of the 
study and gave their consent. 
Assessments. The MADRS, the CGI, and the Patient Global Assess- 
ment (PGA) (Guy 1976) were completed at baseline and after 1, 2, 3, 
4, and 6 weeks of treatment. Vital signs and all adverse experiences 
were also recorded at the same times. The 17-item Hamilton de- 
pression scale (Hamilton 1960) was completed at baseline as well as 
after 4 and 6 weeks of treatment. EKGs and laboratory tests, 
including hepatic and renal balance sheets, were carried out before 
treatment and after 2 and 6 weeks of therapy, while a thorough 
physical examination was performed before and at the end of the 
treatment period. 
Data analysis. A one-way analysis of variance (ANOVA) with treat- 
ment as main effect was used for test for baseline comparability as 
well as differences between treatments for the change from baseline 
in MADRS scores, Hamilton depression total and factor scores, as 
defined by the ECDEU (Guy 1976), and CGI level of severity. 
Categorical data such as dropout rate, level of side effects, and 
demographic characteristics, CGI global improvement, and PGA 
were analyzed with the Fisher's exact test and a responder/ 
nonresponder categorization, using a CGI rating of "much im- 
proved" or "very much improved" as definition of treatment re- 
sponse. The sample size of 106 patients had a power of > 80% to 
detect an average difference of 7 in the MADRS total score between 
nefazodone and amitriptyline. This sample size was based on the 
Student's two sample t-test with an alpha level of 0.05. The error of 
variance (t50) was estimated using data from previous efficacy 
studies. Analyses of the intent-to-treat sample were performed using 
the last observation carried forward (LOCF) as the primary data set 
and visit-wise data set as confirmatory data. Moreover, similar 
confirmatory analyses were performed on the standard efficacy 
sample which excluded patients who discontinued treatment within 
the first 2 weeks. Since the conclusions of the confirmatory analyses 
did not differ from the primary analyses, they will not be reported 
here. Finally, the issue of the treatment by center outcome was 
investigated by assessing the significance of adding a site effect and 
a site by treatment interaction to the statistical models used in the 
LOCF analyses. Computations were performed using the general 
linear model procedure of SAS version 5.18. 
Results 
Dropouts 
A total of 38 pat ients  (35.8%) did no t  complete the study: 
significantly more  pat ients  d iscont inued in the nefazodone 
t rea tment  group (26 or 47%) as compared  to the amitri-  
ptyline t rea tment  group (12 or 24%) (P = 0.015). M a i n  
reasons for d i scont inua t ion  from the s tudy were lack of 
efficacy (10 or 18.2% in the nefazodone group and  4 or 
7.8% in the amitr iptyl ine group, P = 0.15, NS) and  ad- 
verse experience (7 or 12.7% in the nefazodone group and  
2 or 3.9% in the amitr iptyl ine group, P = 0.16, NS). One  
pat ient  in the nefazodone group commit ted  suicide after 
24 days of study treatment .  
Efficacy 
MADRS.  The changes over time on  the M A D R S  in the 
two groups are displayed in Fig. 1. Amitr iptyl ine was 
significantly more effective than  nefazodone (F = 21.63, 
df = 1,101, P = 0.0001) with a t rend already noted  at week 
I(P < 0.1) and  a significant superiori ty (P < 0.01) from 
week 2. The centers did no t  differ in their outcome 
256 
Table 1. Demographic and clinical characteristics of the sample 
Nefazodone group Amitriptyline group F/X 2 P 
n = 55 n = 51 
Age in years (SD) 45.8 (12.6) 48.6 (13.6) 1.29 NS 
Gender (M/F) (%) 27/73 33/67 NS* 
Weight in kg (SD) 65.1 (12.6) 64.7 (11.4) 0.04 NS 
Marital status (%) 
never married 15 10 
married 55 61 
separated/divorced 22 14 
widowed 9 16 0.46 NS 
DSM-III-R characteristics of 
episode (%) 
melancholic 47 65 NS* 
bipolar (296.5 x ) 7 6 NS* 
isolated episode (296.2 x ) 22 24 NS* 
recurrent (296.3 × ) 78 76 NS* 
Duration of present episode (%) 
< 3 months 73 72 
3-5 months 15 16 
> 6 months 13 t2 0.97 NS 
Age at onset of 1st psychiatric 
episode (SD) 36.7 (13.0) 37.8 (14.7) 0.17 NS 
Years since onset of 1st primary 
diagnosis 8.0 (7.2) 11.2 (9.1) 3.45 NS 
Number of previous depressive 
episodes (%) 
none 19 24 
1 26 20 
2-6 46 42 
7-t2 7 10 
>1 12 2 9 0.94 NS 
Previous antidepressant (%) 64 65 NS* 
Prior psychotropie drug (%) 89 88 NS* 




/> 2 45 
Baseline ratings (SD) 
MADRS 34.4 







38 0.36 NS 
35.8 (4.4) 2.18 NS 
28.1. (4.4) 0.15 NS 
5.1 (0.8) 1.02 NS 
*Fisher's exact test 
(F = 0.70, df= 9,82, P = 0.70). The M A D R S  symptom 
profiles at baseline and at endpoint  in the two treatment  
groups are displayed in Fig. 2. 
Hamilton depression scale. The changes over time on the 
Hami l ton  depression scale in the two treatment  groups 
are displayed in Fig. 3. Amitriptyline was significantly 
more  effective than nefazodone (F = 12.97, df= 17,9, 
P -- 0.0006) with greater improvement  after 4 and 6 weeks 
of t reatment  (P < 0.001). The centers did not  differ in their 
outcome (/7 = 0.70, df= 8,61, P = 0.70). The symptom 
profiles at baseline and at endpoint  in the two t reatment  
groups are displayed in Fig. 4. All three factors defined by 
Guy  (1976) exhibited a better improvement  with amitrip- 
tyline as compared  to nefazodone: retardat ion after 
4(P < 0.05) and 6 weeks (P < 0.01) of treatment; anxi- 
ety/somatizat ion after 4 and 6 weeks (P < 0.01); and sleep 
disturbance after 4 (P < 0.1) and 6 weeks (P < 0.05). 
CGI. The changes over time on the C G I  severity of illness 
in the two groups are displayed in Fig. 5. Amitriptyline 
was significantly more  effective than nefazodone 
(F = 18.37, df= 1,101, P = 0.0001), with a trend at week 
2 (P < 0.1) and a significant superiority from week 
3 (P < 0.01). The C G I  global improvement  showed signifi- 
cantly more responders to amitriptyline than to 
nefazodone at weeks 4 (31 or  63.2% versus 19 or 35.1%, 
P = 0.01) and 6 (34 or 69.4% versus 21 or 38.8%, 
P = 0.01). 
PGA. A significantly greater percentage of  patients treated 
with amitriptyline as compared  to nefazodone rated them- 
selves as "much improved"  or  "very much improved"  i.e., 
as "responders", at weeks 3 (27 or 55.1% versus 18 or 
33.3%, P < 0.06), 4 (31 or  63.2% versus 17 or 31.5%, 
P < 0.01) and 6 (32 or 65.3% versus 16 or 29.6%, 
P < 0.01). 
4 0  
3 5  
3 0  
2 5  
2 0  
15  
1 0  
5 
0 i ~ i i i 
0 1 2 3 4 5 6 
Time (weeks) 
Fig. 1. Changes over time in mean scores ( _ SD) on the MADRS 
among patients treated by nefazodone or amitriptyline. , nefa- 
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Fig. 3. Changes over time in mean scores ( + SD) on the Hamilton 
depression scale among patients treated by nefazodone or amitripty- 
line. - - ,  nefazodone; .. . .  amitriptyline 
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Fig. 2. Individual MADRS items: profile at baseline (upper part) and 
at endpoint (lower part) among patients treated with nefazodone 
or amitriptyline. MADRS items: 1, apparent sadness; 2, reported 
sadness; 3, inner tension; 4, reduced sleep; 5, reduced appetite, 
6, concentration difficulties; 7, lassitude; 8, inability to feel; 9, pessi- 
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Fig. 4. Individual Hamilton depression scale items: profile at base- 
line (upper part) and at endpoint (lower part) among patients treated 
with nefazodone or amitriptyline. Hamilton depression scale items: 
1, depressed mood; 2, feeling of guilt; 3, suicide; 4, initial insomnia; 5, 
middle insomnia; 6, delayed insomnia; 7, work and interests; 8, 
retardation; 9, agitation; 10, anxiety (psychological); 11, anxiety 
(somatic); 12, somatic symptoms (gastrointestinal); 13, somatic 
symptoms (general); 14, toss of libido; 15, hypochondriasis; 16, 
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Fig. 5. Changes over time in mean scores (_+ SD) on the CGI 
severity of illness among patients treated by nefazodone or amitri- 
p ty l ine . - - ,  nefazodone; .... amitriptyline 
Safety 
The comparison of the frequency of side effects in the two 
treatment groups is presented in Table 2. Dry mouth was 
significantly more often reported with amitriptyline than 
with nefazodone. 
Physical examinations did not show any finding of 
medical importance. Blood pressure did not exhibit signif- 
icant changes during the study and EKGs and laboratory 
tests did not reveal significant alterations. 
Dosage 
Mean nefazodone daily doses (SD) were 191.7 mg (42.1) 
during week 1, 218.9 mg (60.6) during week 2, 244.6mg 
(79.0) during week 3, 266.2 mg (81.7) during week 4, and 
242 mg (86.5) at week 6; corresponding doses for amitrip- 
tyline were, respectively, 96.4 mg (23.9), 106.6 mg (26.4), 
t19.4 mg (34.1), 125.0 mg (35.4), and 124.4 mg (38.5). Mo- 
dal daily doses within the last treatment week increased 
significantly in the 27 patients included after the protocol 
mendment as compared to the 79 previous ones (F = 3.85, 
df = 1, 99, P -- 0.05); this increase was however only stat- 
istically significant in the nefazodone group: from 225.0 to 
296.4 mg (P < 0.001) and not in the amitriptyline group: 
from 116.7 to 132.7 mg. 
Discussion 
The results o f  the present study show that nefazodone at 
a final modal daily dose of 242 mg is significantly less 
effective than amitriptyline at a final modal daily dose of 
124 mg in major depressive inpatients. Indeed, all rating 
instruments favor amitriptyline over nefazodone: 
MADRS, Hamilton depression scale including retarda- 
tion, anxiety, and sleep disturbance factors, CGI, and 
PGA. Moreover, the conclusions from the analysis of the 
visit-wise data set are not different from the intent-to-treat 
(LOCF) analysis, a surprising finding considering the 
large number of dropouts, particularly in the nefazodone 
group, which demonstrates that not only was nefazodone 
responsible for more dropout  for inefficacy but that it was 
also much less effective than amitriptyline in the patients 
who completed the 6-week trial. These findings contradict 
US trials where nefazodone was found significantly more 
effective than placebo and equivalent to imipramine 
(Feighner et al. 1989; D'Amico et al. 1990). 
These discrepancies could be explained in two ways. 
First, the dosage of nefazodone in the present study could 
have been selected below the optimal therapeutic dose. 
Supporting this hypothesis, a recent study by Fontaine 
et al. (1991) comparing low-dose nefazodone (final modal 
daily dose = 246 rag), high-dose nefazodone (final modal 
daily dose = 462mg), imipramine (final modal daily 
dose = 216 rag), and placebo in depressive outpatients 
found no significant differences in efficacy between low- 
dose nefazodone and placebo, whereas high-dose 
nefazodone was more effective than placebo and equiva- 
lent to imipramine. It should be noted that the nefazodone 
modal daily "low dose" in Fontaine's study was quite 
Table 2. Comparison of the frequency of adverse 
events (%) Nefazodone group Amitriptyline group P* 
n = 55 n = 51 
Body as a whole 
headache 9.1 
abdominal pain 5.5 
Digestive system 
nausea 14.6 


















*Fischer's exact test 
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similar to the nefazodone dose used in our trial: respec- 
tively, 246 and 242 mg. The selection of the nefazodone 
dose range for our study was based on a dose-ranging 
study comparing fixed doses of nefazodone 50, 100, 200, 
and 300 mg daily with placebo which demonstrated a sig- 
nificant efficacy for both the 100 mg and 200 mg doses but 
a tack of improvement in the 50 mg and more unexpected- 
ly in the 300 mg groups (D'Amico et al. 1990). 
An alternative explanation in these discrepancies re- 
garding nefazodone efficacy between our trim and the 
previous published reports is that patients included in 
European studies greatly differ from US patients in terms 
of type of recruitment, severity, symptom profile, presence 
of endogenous features, socio-economic origin, family, 
social, and professional adjustment, personality disturb- 
ances (Ansseau 1992) and could respond tess to atypical 
antidepressants. For example, in our study, mean 17-item 
Hamilton depression scores were 27.8 for DSM-II-R non- 
melancholic major depressive patients and 28.3 for melan- 
cholic patients; in comparison, the mean Hamilton rating 
of US patients involved in similar comparative studies of 
nefazodone was 23.6 for nonmelancholic major depressive 
patients (n = 838) and 25.0 for melancholic patients 
(n = 938) (von Frenckell et al. 1992). Yet caution is war- 
ranted in assuming actual differences in illness severity 
due to the lack of studies of interrater reliability between 
Europe and the US. Our personal experience in psychi- 
atric departments both in the US and in Belgium, how- 
ever, found a tendency to rate higher among US clinicians. 
Moreover, a recent comparison of scores on the individual 
17 items of the Hamilton depression scale using the 
nefazodone database revealed 10 items significantly high- 
er among the 473 European patients (depressed mood, 
suicide, delayed insomnia, work and interests, 
retardation, psychic anxiety, gastrointestinal symptoms, 
hypochondriasis, weight loss, and loss of insight) and 
5 items with higher scores among the 1778 US patients 
(feeling of guilt, middle insomnia, somatic anxiety, general 
somatic symptoms, and loss of libido) (von Frenckell et al. 
1992). A elegant method to resolve possible differences in 
rating between European and US psychiatrists could be 
the use of self-rating scales. Unfortunately, none of them 
was included in the current protocol. It should be noted, 
however, that they are very often difficult to complete for 
severely depressed inpatients; moreover, their sensitivity 
to cliniCal changes is generally lower than observers' rat- 
ing scales (Bobon 1987). 
Studies involving hospitalized depressive patients are 
also much more common in Europe. Depressive in- 
patients tend to be much more homogeneous, display high 
level of severity, endogenous features, and suicidal idea- 
tion (von Frenckell et al. 1992). They are less responsive to 
placebos, benzodiazepines, and more importantly to "mi- 
nor" antidepressants (Ansseau 1992). Indeed, during the 
1970s, a number of compounds chemically and pharmaco- 
logically different from the tricyclics have been proposed 
as antidepressants. Although several of these compounds, 
such as viloxazine, mianserine, or trazodone, have been in 
general use for some years, their clinical efficacy has been 
seriously questioned, mainly on the basis of analyses of the 
clinical trials (Kragh-Sorensen et al. 1983). In our study, 
65 % of the patients were resistant to previous antidepress- 
ants whereas most US studies include drug-naive patients. 
Depressive inpatients appear therefore particularly suited 
for testing the antidepressant potential of new compounds 
(Ansseau et al. 1991). 
Interestingly, several European studies of new antide- 
pressant drugs found an efficacy lower than reference 
tricyctics in hospitalized patients. As examples, three 
independent trials conducted by the Danish University 
Antidepressant Group found the selective 5-HT reuptake 
inhibitors citalopram and paroxetine as well as the revers- 
ible MAO-A inhibitor moclobemide weaker antidepress- 
ants than clomipramine (Danish University Antidepress- 
ant Group 1986, 1990, 1993). These results also contrast 
the majority of studies on citalopram, paroxetine, and 
moclobemide (Dechant and Clissold 1991; Milne and Goa 
1991; Fitton et al. 1992). When analysing the differences in 
outcome between their studies and the literature on these 
new antidepressants, the authors raise the possibility of 
differences in patient populations, rating methodology, 
spontaneous recovery, dosing, trial quality, and sample 
size (Danish University Antideperssant Group 1993). The 
only demonstrated difference, however, is that the studies 
performed by the Danish University Antidepressant 
Group differ from the vast majority in the field by only 
including hospitalized patients which may represent a dif- 
ferent type of depression (Danish University Antidepress- 
ant Group 1993). The authors advocate a strong need for 
revised standards for the conduction of clinical trials with 
antidepressants, including a more detailed account on 
patient recruitment and background variables and 
tightening up of several methodological facets (Danish 
University Antidepressant Group 1993). Our present 
study confirms that such methodology may eventually 
lead to more conclusive efficacy studies on antidepress- 
ants. The differences in the selection process and in the 
clinical characteristics of the patients might explain the 
contradictory results obtained in our study and in US 
trials. 
Several limitations in the design in the present study 
should be acknowledged and discussed. First, the lack of 
a placebo-treated group makes it necessary to interpret 
very cautiously all data concerning efficacy. A placebo 
arm would have enabled us to assess whether nefazodone 
exhibits any effect in this patient sample as opposed to 
results in earlier studies. Second, an amendment changes 
the titration schedule of the study in the last quarter of 
patients included. This amendment was based on an blind 
interim analysis of the 69 first patients showing a rather 
low overall response (6t%), possibly related to lower 
dosage during the first 2 weeks in the nonresponders. The 
global response rate did not improve, however, after this 
amendment, reaching only 53% for the whole sample. 
This global rate results from very different responses in the 
two groups: 39% with nefazodone and 69% with amitrip- 
tyline. Third, the inclusion of elderly depressive patients 
can be criticized, particularly in view of the age-related 
modifications of nefazodone pharmacokinetics. It should 
be noted, however, that the dose of nefazodone was indi- 
vidually adapted and considered to the optimal for each 
patient. Moreover, until now, the efficacy and tolerability 
of nefazodone have never been specifically assessed in 
elderly depressive patients. Fourth, the use of flexible 
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dosage is another  problem which should be emphasized. 
The t i tration of  the dose on the basis of  the clinical 
response and the adverse experience profile of  each pa- 
tient can in many  ways seem irrelevant. Indeed, adverse 
events can appear  on subtherapeutic doses of tricyclic 
antidepressants and the therapeutic effect is delayed by up 
to 4 -6  weeks (Gram 1990). 
In our  study, the tolerance of nefazodone was better 
than amitriptyline with regard to anticholinergic side ef- 
fects, particularly dry mouth.  These findings confirm the 
previous trials which showed a much lower incidence of  
adverse events as compared  to imipramine (Feighner et al. 
1989; Fonta ine  1992). Interestingly, the level of  digestive 
adverse events associated with nefazodone in our  study 
was very low, what  clearly distinguishes nefazodone from 
selective 5-HT reuptake blockers such as fluoxetine (Be- 
nfield et al. 1986). 
In conclusion, the present study suggests lower efficacy 
but better tolerance of  nefazodone as compared  to a refer- 
ence tricyclic. The reasons for this lower efficacy as com- 
pared to previous trials, either due to a dose below the 
opt imal  range or  to part icular  characteristics of  European  
patients, should be carefully evaluated in further trials. 
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